keyword
MENU ▼
Read by QxMD icon Read
search

Phase 3 cancer

keyword
https://www.readbyqxmd.com/read/29050275/alisol-b-23-acetate-induces-autophagic-dependent-apoptosis-in-human-colon-cancer-cells-via-ros-generation-and-jnk-activation
#1
Yueliang Zhao, Edmund T S Li, Mingfu Wang
Alisol B 23-acetate (AB23A), a natural triterpenoid from the rhizome of Alisma orientale, a Chinese medicinal herb, has multiple physiological activities including anticancer. However, its effect on human colon cancer and the underlying mechanism are not clear. Here, we reported for the first time that AB23A induced cell cycle G1 phase arrest and apoptotic cell death in colon cancer cells. Autophagy also occurred in AB23A-treated HCT116 cells as evidenced by the accumulation of microtubule-associated protein 1 light chain 3 form II (LC3-II) and degradation of SQSTM1/p62...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050231/a-phase-i-study-of-foretinib-plus-erlotinib-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-canadian-cancer-trials-group-ind-196
#2
Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, Dongsheng Tu, Cheryl Ho, Frances A Shepherd, Nevin Murray, John R Goffin, Garth Nicholas, Shingo Sakashita, Zhuo Chen, Lucia Kim, Jean Powers, Lesley Seymour, Glenwood Goss, Penelope A Bradbury
PURPOSE: MET and AXL mediate resistance to EGFR TKI in NSCLC. Foretinib, a MET/RON/AXL/TIE-2/VEGFR kinase inhibitor may overcome EGFR kinase resistance. This dose escalation study combined foretinib and erlotinib in advanced pretreated NSCLC patients. EXPERIMENTAL DESIGN: The primary endpoint was to define the RP2D of foretinib plus erlotinib as continuous oral daily dosing. Secondary objectives included safety, pharmacokinetics, response and potential biomarkers of response including EGFR, KRAS genotype, MET, AXL expression, and circulating HGF levels...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29049999/luteolin-promotes-cell-apoptosis-by-inducing-autophagy-in-hepatocellular-carcinoma
#3
Zhijia Cao, Huainian Zhang, Xiaoyan Cai, Wei Fang, Dong Chai, Ying Wen, Hongsheng Chen, Fujiang Chu, Yongli Zhang
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. Luteolin, a flavonoid from traditional Chinese medicine, shows anti-cancer activity in many cancer cells, including HCC. However, the mechanism underlying the action of luteolin in HCC, especially its role in regulating cell autophagy, remains unclear. In the present study, we investigated the role of luteolin in regulating cell autophagy and the role of autophagy in luteolin-induced apoptosis...
October 19, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29048673/the-ethanol-extracts-of-sporoderm-broken-spores-of-ganoderma-lucidum-inhibit-colorectal-cancer-in-vitro-and-in-vivo
#4
Kang Li, Kun Na, Tingting Sang, Kaikai Wu, Ying Wang, Xingya Wang
The medicinal mushroom Ganoderma lucidum (G. lucidum) has been reported to possess a variety of pharmacological activities including anticancer effects. However, the anti-colorectal cancer effects and the potential molecular mechanisms of the ethanol extracts of sporoderm-broken spores of G. lucidum (BSGLEE), which mainly contains triterpenoids, have not been reported. The aim of the present study was to investigate the anticancer effects and molecular mechanisms exerted by BSGLEE on colorectal cancer in vitro and in vivo...
September 27, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29048667/inhibitory-effect-of-black-tea-pigments-theaflavin%C3%A2-3-3-gallate-against-cisplatin-resistant-ovarian-cancer-cells-by-inducing-apoptosis-and-g1-cell-cycle-arrest
#5
Haibo Pan, Fang Wang, Gary O Rankin, Yon Rojanasakul, Youying Tu, Yi Charlie Chen
Adverse side effects and acquired resistance to conventional chemotherapy based on platinum drive the exploration of other selective anticancer drugs. Theaflavin‑3-gallate (TF2a) and theaflavin‑3'-gallate (TF2b), theaflavin monomers in black tea, exhibited a potent growth inhibitory effect on cisplatin-resistant ovarian cancer A2780/CP70 cells and were less cytotoxic to normal ovarian IOSE-364 cell line. Flow cytometry analysis and western blotting indicated that TF2a and TF2b induced apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells...
October 3, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29048662/capsaicin-inhibits-proliferation-and-induces-apoptosis-in-osteosarcoma-cell-lines-via-the-mitogen%C3%A2-activated-protein-kinase-pathway
#6
Yuan Zhang, Xu Deng, Tao Lei, Chang Yu, Yang Wang, Guosheng Zhao, Xiaoji Luo, Ke Tang, Zhengxue Quan, Dianming Jiang
Capsaicin, a pungent molecular compound present in many hot peppers, exerts anticancer activities against various human cancer cell lines by inducing apoptosis. However, the effects of capsaicin on human osteosarcoma (OS) as well as the related mechanisms remain to be fully elucidated. In the present study, the anticancer effects of capsaicin on 3 human OS cell lines (MG63, 143B and HOS) were investigated. Various concentrations of capsaicin (50-300 µM) effectively decreased cell viability in all 3 OS cell lines in a dose-dependent manner...
September 18, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29048622/enhancement-of-cytotoxic-effects-of-gemcitabine-by-dclk1-inhibition-through-suppression-of-chk1-phosphorylation-in-human-pancreatic-cancer-cells
#7
Daichi Kawamura, Yoshihiro Takemoto, Arata Nishimoto, Koji Ueno, Tohru Hosoyama, Bungo Shirasawa, Toshiki Tanaka, Naruji Kugimiya, Eijiro Harada, Kimikazu Hamano
Although gemcitabine (GEM) is frequently used in the treatment of pancreatic cancer, the effects are limited. To increase the inhibitory effect of GEM, the identification of a molecular target is needed. Recent studies have revealed that doublecortin-like kinase 1 (Dclk1) positively regulates tumor growth, invasion, metastasis, factors related to epithelial-mesenchymal transition (EMT), pluripotency, angiogenesis, and anti-apoptosis in pancreatic cancer cells. Therefore, Dclk1 is a potential therapeutic target for pancreatic cancer...
September 20, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29048616/the-receptor-for-activated-protein-kinase-c-promotes-cell-growth-invasion-and-migration-in-cervical-cancer
#8
Shan Liao, Songshu Xiao, Hongxiang Chen, Manying Zhang, Zhifang Chen, Yuehua Long, Lu Gao, Junyu He, Yanshan Ge, Wei Yi, Minghua Wu, Guiyuan Li, Yanhong Zhou
Cervical cancer is one of the most common malignant tumors in women all over the world. However, the exact etiology of cervical cancer remains unclear. The receptor for activated protein kinase C (RACK1) is reported to be involved in tumorigenesis and tumor progression. Besides, the prognostic value of RACK1 in several kinds of tumors has been identified. However, there are limited studies on the functional role of RACK1 in cervical cancer. In this study, we tested the expression level of RACK1 by immunohistochemistry and western blot technologies and find that it is upregulated in cervical cancer...
September 27, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29048237/lenvatinib-for-the-treatment-of-radio-iodine-refractory-thyroid-cancer-in-real-life-practice
#9
Amandine Berdelou, Isabelle Borget, Yann Godbert, Thierry Nguyen, Marie-Eve Garcia, Cecile N Chougnet, Aurélie Ferru, Camille Buffet, Olivier Chabre, Olivier Huillard, Sophie Leboulleux, Martin Schlumberger
BACKGROUND: In the SELECT phase III trial in advanced radio-iodine refractory differentiated thyroid cancer (rDTC), lenvatinib improved median progression free survival (PFS) over placebo by almost 15 months and induces an objective response rate of 64.8%, but adverse events occurred in almost all patients. The present study evaluates the efficacy and toxicity of lenvatinib treatment in real-life practice. METHODS: Clinical charts of 88 consecutive patients treated with lenvatinib from July 2015 to June 2016 in 27 French centers were retrospectively reviewed...
October 19, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29047238/identification-of-10-candidate-biomarkers-distinguishing-tuberculous-and-malignant-pleural-fluid-by-proteomic-methods
#10
Chang Youl Lee, Ji Young Hong, Myung Goo Lee, In Bum Suh
PURPOSE: Pleural effusion, an accumulation of fluid in the pleural space, usually occurs in patients when the rate of fluid formation exceeds the rate of fluid removal. The differential diagnosis of tuberculous pleurisy and malignant pleural effusion is a difficult task in high tuberculous prevalence areas. The aim of the present study was to identify novel biomarkers for the diagnosis of pleural fluid using proteomics technology. MATERIALS AND METHODS: We used samples from five patients with transudative pleural effusions for internal standard, five patients with tuberculous pleurisy, and the same numbers of patients having malignant effusions were enrolled in the study...
November 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29047142/relevance-of-liver-limited-disease-in-metastatic-colorectal-cancer-subgroup-findings-of-the-fire-3-aio-krk0306-trial
#11
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Michael Scholz, Sebastian Müller, Hartmut Link, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Lisa Miller-Phillips, Thomas Kirchner, Andreas Jung, Jobst Christian von Einem, Dominik Paul Modest, Volker Heinemann
In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of initially unresectable LLD with regard to targeted first-line therapy. The present analysis investigated the relevance of initially unresectable LLD in mCRC patients treated with targeted therapy against either the epidermal growth factor receptor (EGFR) or vascular epithelial growth factor (VEGF)...
October 19, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29047029/phase-i-study-of-the-combination-of-crizotinib-as-a-met-inhibitor-and-dasatinib-as-a-c-src-inhibitor-in-patients-with-advanced-cancer
#12
Shumei Kato, Denis L Jardim, Faye M Johnson, Vivek Subbiah, Sarina Piha-Paul, Apostolia M Tsimberidou, Gerald S Falchook, Daniel Karp, Ralph Zinner, Jennifer Wheler, Filip Janku, Siqing Fu, JoAnn Lim, Stacie Bean, Ly Nguyen, Susan Urban, Elsa Browne, Funda Meric-Bernstam, David S Hong
Background Both MET and c-SRC are important mediators of cancer progression and there is cross talk between the two molecules. Preclinical studies have demonstrated combination of MET and c-SRC inhibitors is effective in multiple cancer types. Methods We analyzed the safety and efficacy of administering a c-SRC inhibitor (dasatinib) in combination with a MET inhibitor (crizotinib) in a two-arm concurrent phase I study. Arm A consisted of crizotinib fixed at 250 mg twice per day with escalation of dasatinib...
October 19, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29046955/the-relationship-between-child-and-caregiver-sleep-in-acute-lymphoblastic-leukemia-maintenance
#13
Lauren C Daniel, Colleen M Walsh, Lisa J Meltzer, Lamia P Barakat, Jacqueline D Kloss
PURPOSE: The purposes of this study are to describe sleep quality and sleep disturbance among caregivers of children in the maintenance phase of acute lymphoblastic leukemia (ALL) and to examine the relationship between sleep quality, child sleep disturbance, and caregiver guilt and worry. METHODS: Caregivers of 68 children with ALL, ages 3 to 12 years old, completed measures of caregiver guilt and worry, caregiver sleep quality, and child's developmental history and sleep habits...
October 18, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29046247/optimal-usage-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#14
REVIEW
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58-0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastases-with a comparable safety profile. To optimize treatment outcomes, selection of appropriate patients is important...
October 15, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29045659/bevacizumab-chemotherapy-versus-chemotherapy-alone-in-elderly-patients-with-untreated-metastatic-colorectal-cancer-a-randomized-phase-ii-trial-prodige-20-study-results
#15
T Aparicio, O Bouché, J Taieb, E Maillard, S Kirscher, P-L Etienne, R Faroux, F Akouz Khemissa, F El Hajbi, C Locher, Y Rinaldi, T Lecomte, S Lavau-Denes, M Baconnier, A Oden-Gangloff, D Genet, E Paillaud, F Retornaz, E François, L Bedenne
BACKGROUND: Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific endpoints in this population. PATIENTS AND METHODS: Patients aged 75 and over were randomly assigned to bevacizumab + chemotherapy (BEV) versus chemotherapy (CT)...
September 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045554/veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus-placebo-with-carboplatin-paclitaxel-in-patients-with-brca1-2-locally-recurrent-metastatic-breast-cancer-randomized-phase-ii-study
#16
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli, S M Domchek, M Friedlander, B Kaufman, J E Garber, Y Shparyk, E Chmielowska, E H Jakobsen, V Kaklamani, W Gradishar, C K Ratajczak, C Nickner, Q Qin, J Qian, S P Shepherd, S J Isakoff, S Puhalla
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045540/phase-ii-trial-of-pembrolizumab-in-patients-with-platinum-refractory-germ-cell-tumors-a-hoosier-cancer-research-network-study-gu14-206
#17
N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. Patients and Methods: Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease progression in patients with relapsed GCT and no curable options...
October 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045535/select-2-a-phase-ii-double-blind-randomised-placebo-controlled-study-to-assess-the-efficacy-of-selumetinib-plus-docetaxel-as-a-second-line-treatment-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer
#18
J C Soria, A Fülöp, C Maciel, J R Fischer, G Girotto, S Lago, E Smit, G Ostoros, W E E Eberhardt, P Lishkovska, S Lovick, G Mariani, A McKeown, E Kilgour, P Smith, K Bowen, A Kohlmann, D J Carlile, P A Jänne
Background: Combination of selumetinib plus docetaxel provided clinical benefit in a previous Phase II trial for patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC). The Phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. Patients and methods: Patients who had disease progression after first-line anti-cancer therapy were randomised (2:2:1) to selumetinib 75 mg BID plus docetaxel 60 mg/m2 or 75 mg/m2 (SEL+DOC 60; SEL+DOC 75), or placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)...
October 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045529/impact-of-genetic-variations-in-the-mapk-signaling-pathway-on-outcome-in-metastatic-colorectal-cancer-patients-treated-with-first-line-folfiri-and-bevacizumab-data-from-fire-3-and-tribe-trials
#19
M D Berger, S Stintzing, V Heinemann, D Yang, S Cao, Y Sunakawa, Y Ning, S Matsusaka, S Okazaki, Y Miyamoto, M Suenaga, M Schirripa, S Soni, W Zhang, A Falcone, F Loupakis, H-J Lenz
Background: The MAPK-interacting kinase 1 (MKNK1) is localized downstream of the RAS/RAF/ERK and the MAP3K1/MKK/p38 signaling pathway. Through phosphorylation MKNK1 regulates the function of eukaryotic translation initiation factor 4E, a key player in translational control, whose expression is often upregulated in metastatic colorectal cancer patients (mCRC). Preclinical data suggest that MKNK1 increases angiogenesis by upregulating angiogenic factors. We therefore hypothesize that variations in the MKNK1 gene predict outcome in mCRC patients treated with first-line FOLFIRI and bevacizumab (bev)...
August 2, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045520/overall-survival-analysis-of-exam-a-phase-3-trial-of-cabozantinib-in-patients-with-radiographically-progressive-medullary-thyroid-carcinoma
#20
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle, E E W Cohen, L Wirth, H Ali, D O Clary, Y Yaron, M Mangeshkar, D Ball, B Nelkin, S Sherman
Background: Primary analysis of the double-blind, phase 3 EXAM trial demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was performed after long-term follow-up. Patients and Methods: EXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC...
September 22, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
17437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"